GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders
Lorenzo Leggio(National Institute on Drug Abuse), W. Kyle Simmons(Oklahoma State University Medical Center), Anders Fink‐Jensen(Bispebjerg Hospital), Mehdi Farokhnia(National Institute on Drug Abuse), Mette Kruse Klausen(Frederiksberg Hospital), Joseph P. Schacht(University of Colorado Denver), Christian S. Hendershot(University of North Carolina at Chapel Hill)
Cited by 83
Related Papers
Common variants conferring risk of schizophrenia
|Nature|2009|1.7k
Interventions and Manipulations of Interoception
|Trends in Neurosciences|2020|250
Oxytocin by intranasal and intravenous routes reaches the cerebrospinal fluid in rhesus macaques: determination using a novel oxytocin assay
|Molecular Psychiatry|2017|241
The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission
|JCI Insight|2023|200
Sex Differences in Opioid and Psychostimulant Craving and Relapse: A Critical Review
|Pharmacological Reviews|2022|155